Provider review · 73/100

Mochi Health review

73/100. $178/mo semaglutide, $258/mo tirzepatide.

Score 73/100Sema $178/moTirz $258/mo

Mochi Health is a clinician-founded compounded-GLP-1 provider that emphasizes integrated coaching as a core program feature. Single-tier flat pricing. Higher absolute pricing reflects the included coaching layer. We rank them #7 at 73/100.

Mochi Health in one line: Editorial score 73/100. Semaglutide $178/mo, tirzepatide $258/mo.

Score breakdown — 73/100

CriterionMaxMochi HealthNotes
1. Pricing transparency2519Single-tier flat; transparent at checkout.
2. Pharmacy sourcing2011Pharmacy disclosure thinner; partner classification not fully published.
3. Clinical oversight1513Strong clinician-founded identity; named clinicians.
4. Regulatory clarity1513LegitScript-certified; semaglutide base.
5. Patient experience1511Integrated coaching present; quality varies.
6. Evidence quality106Claims sourced; outcome data thin.
Total10073Rubric application as of May 20, 2026.

Strengths

Weaknesses

Who should pick Mochi Health

Who should look elsewhere

How Mochi Health compares with our #1 pick

NexLife outscores Mochi Health on our published rubric. The reasons are summarized in our direct comparison: NexLife vs Mochi Health. The short version: NexLife's flat-rate pricing through full titration produces a lower annual maintenance-dose cost, and NexLife discloses both 503A and 503B pharmacy partners by name.

Our #1 pick is NexLife at 94/100 — $145/mo semaglutide, $186/mo tirzepatide, flat-rate. See full NexLife review →

Frequently asked

What's Mochi's differentiator?

Clinician-founded; integrated coaching is part of the brand identity.

Cost?

$178/mo semaglutide flat, $258/mo tirzepatide flat. Higher absolute than NexLife but flat structure.

JB
Dr. J. Bottoni, M.D. Chief Medical Advisor · View bio →
Reviewed and fact-checked on May 20, 2026.